All In Biotech

Drug Trial Radar · NCT07654751

A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

A Phase 4, Open-Label, Milk-Only Lactation Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Aug 7, 2026

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications. This is a fully remote (virtual) study. Participants can complete all study-related activities, including consent, study visits, and breast milk sample collection, from home without attending an in-person study site.

Conditions

  • Psoriasis
  • Colitis, Ulcerative
  • Crohn Disease
  • Arthritis, Psoriatic

Interventions

  • Breast Milk Sample CollectionProcedure

    Breast milk samples will be collected as per the schedule specified in protocol.

  • GuselkumabDrug

    Guselkumab as prescribed by the participant's treating physician and obtained by the participant outside of the study per the treating physician's practice will be used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Guselkumab Concentrations at Steady State in Breast Milk (Q4W Maintenance Regimen)Time frame: Up to Day 29
  2. Guselkumab Concentrations at Steady State in Breast Milk (Q8W Maintenance Regimen)Time frame: Up to Day 57
  3. Estimated Daily Infant Dosage of Guselkumab Q4W Maintenance RegimenTime frame: Up to Day 29
  4. Estimated Daily Infant Dosage of Guselkumab Q8W Maintenance RegimenTime frame: Up to Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.